The Effectiveness of “Two-Week” Referrals for Suspected Bone and Soft Tissue Sarcoma by Malik, A. et al.
Hindawi Publishing Corporation
Sarcoma
Volume 2007, Article ID 23870, 3 pages
doi:10.1155/2007/23870
ClinicalStudy
The Effectiveness of “Two-Week” Referrals for
Suspected Bone and Soft Tissue Sarcoma
A. Malik, L. Wigney, S. Murray, and C. H. Gerrand
North of England Bone and Soft Tissue Tumour Service, Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK
Correspondence should be addressed to C. H. Gerrand, craig.gerrand@nuth.nhs.uk
Received 6 May 2007; Accepted 14 November 2007
Recommended by Michael Leahy
Thetwo-week“wait”targetintroducedin2000requiresthatpatientswithsuspectedcancerreferredbygeneralpractitionersshould
be seen within two weeks. We reviewed patients who had been referred under this standard to the North of England Bone and Soft
Tissue Tumour Service, to determine if the referral guidelines had been followed, and what proportion of patients referred under
the guideline had malignant tumours. 40 patients were referred under the guideline between January 2004 and December 2005.
Ten of these patients (2548%) had malignant tumours, compared with 243 of 507 (48%) of those referred from other sources. In 9
of the 40 cases, the patient did not meet the criteria for urgent referral. Although this target has focussed attention on shortening
the time to diagnosis and treatment, prioritising patients referred from general practitioners has the potential to disadvantage
those with malignant tumours referred from other sources.
Copyright © 2007 A. Malik et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
The NHS Cancer Plan [1] was published in September 2000.
Thisdocumentdetailedthegovernment’scomprehensivena-
tional programme for investment in and reform of cancer
services in the NHS. Amongst other reforms, there has been
a drive to reduce the waiting time of cancer patients from
referral to diagnosis and treatment in a stepwise manner. A
maximum two-week wait target for an outpatient appoint-
ment for patients with suspected breast cancer has been in
place since April 1999. This has been sequentially rolled out




an urgent referral and the initiation of treatment deﬁned as
the ﬁrst diagnostic investigation or treatment intervention.
The ﬁnal target, to be achieved by 2008, is that there should
be a maximum wait of 31 days between urgent referral and
the initiation of treatment.
Department of Health (DoH) guidelines state that if a
soft tissue mass is greater than 5 centimetres in maximum
dimension, is deep to the investing fascia, is painful, is being
enlarging, or has recurred after previous excision, the patient
should be referred under the “two-week” rule [2]. Patients
with suspected bone tumours should also be referred under
this rule if there are abnormal x-ray ﬁndings [2].
As a tertiary referral centre for bone and soft tissue tu-
mours, we receive referrals from a wide variety of sources,
including primary care and other hospital consultants. The
primary aim of this study was to determine what proportion
ofnewreferralshadbeenmadetoourcentreunderthe“two-
week” rule and what proportion of these patients had ma-
lignant tumours. Secondary aims were to determine whether
patients being referredunder this rulemet thereferralguide-
lines, and whether targets for the time from referral to being
seen in outpatients and from referral to ﬁrst diagnostic in-
vestigation or treatment were being met.
2. METHODS
We reviewed the case notes of all patients referred under the
“two-week” rule to the North of England Bone and Soft Tis-
sue Tumour Service between January 2004 and December
2005. The referral letters were evaluated to see if they met
DoH guidelines for referral of a suspected bone or soft tissue
tumour[2].Casenoteswereusedtodeterminethefollowing:
theﬁnaldiagnosis,timeelapsedbetweenthereferralandﬁrst2 Sarcoma
Table 1: Distribution of diagnostic categories for each referral route.
Route of referral Primary tumour malignant Primary tumour benign Metastatic tumour Nonneoplastic Total
“Two-week” rule 6 (15%) 12 (30.5%) 4 (7.5%) 18 (46%) 40
Other 175 (35%) 220 (43%) 68 (13%) 44 (8%) 507
Table 2: Frequency with which clinical features in DoH referral
guidelines appeared in referral letters and after review in our cen-
tre.
Feature Frequency in letter Frequency in clinic
Size > 5cms 24 (60%) 20 (50%)
Pain 22 (55%) 14 (35%)
Increase in size 19 (47.5%) 18 (45%)
Deep to fascia 32 (80%) 26 (65%)
Recurrence 0 (0%) 0 (0%)
Suspicious X-rays 8 (20%) 8 (20%)
None 9 (22.5%) 7 (17.5%)
clinic appointment, and the time elapsed between the refer-
ral and the ﬁrst diagnostic investigation or treatment. The
total number of referrals to the unit and their diagnosis dur-
ing this two-year period was obtained from a computerised
database.
3. RESULTS
Between January 2004 and December 2005, a total of 40 pa-
tients were seen under the “two-week” rule. During the same
time period, 507 patients were referred by other routes. The
ﬁnal diagnoses for each group are shown in Table 1.
The frequency with which patients had the features de-
scribed intheguidelines mentioned inthereferrallettersand
the frequency with which these features were detected in the
clinicareshowninTable 2.Most(31of40,78%)“two-week”
referralsmetthepublishedreferralguidelines.However,nine
referrals under the rule did not mention any of the guide-
line features. None of these nine patients had malignant tu-
mours. All of the malignant tumours referred under the rule
had at least one of the features in the guidelines requiring ur-
gent referral. Eight (20%) of the “two-week” referrals were
prompted by suspicious radiological ﬁndings, reported by
nonspecialist radiologists. Two of these patients had osteo-
chondromata and six had nonneoplastic lesions (stress frac-
ture, cortical sclerosis, medial meniscal cyst, or phlebolith).
A number of 38 of the 40 (95%) patients referred under
the “two-week” rule were seen within 14 days (1 to 20 days)
followingreceiptofthereferralletter.Therewasadelayinre-
ceivingthereferralforthetwopatientsthatwereseenbeyond
the two-week target. The median time between referral and
ﬁrst investigation or initiation of treatment for this group
was 39 days (range 4 to 358 days). 27 of these 40 (68%) re-
ferrals had their treatment initiated or ﬁrst investigation per-
formedwithin62daysofreferral.Allofthepatientswithma-
lignant tumours in this group had treatment initiated within
30 days of referral.
4. DISCUSSION
Our study shows that the proportion of patients referred to
our centre under the “two-week” rule is small (less than a
twelfth of the total referrals to the unit). Similarly, the pro-
portion of patients referred under this rule who have ma-
lignant tumours is low (6 of 40, 15%). The majority of pa-
tients referred to our centre come by other routes, and the
proportion of patients with malignant tumours referred in
this manner is higher (177 of 507, 35%). 9 of 40 (23%) of
the referrals made under the “two-week” rule failed to men-
tion any of the DoH guideline requirements for urgent re-
ferral; none of these patients had malignant tumours. Al-
most all patients referred under the “two-week” rule were
seen within two weeks. All patients with malignant tumours
were treated or had their ﬁrst investigation within 30 days of
referral. However, overall only 27 of the 40 (68%) patients
referred under the “two-week” rule had their treatment ini-
tiated or their ﬁrst investigation performed within 62 days of
referral.
Boneandsofttissuesarcomasareraretumours.Enzinger
and Weiss [3] suggested that there are atleast 100 benign soft
tissue tumours for every malignant tumour examined by a
pathologist. The incidence of benign soft tissue tumors is
about 300 per 100,000 population [4]. A general practitioner
(GP) with a practice of 3000 patients might expect to see
at least three patients with benign soft tissue tumors every
year. However, the same GP would only expect to see one
patient with a soft tissue sarcoma every 24 years [5]. Diag-
nosing a malignant soft tissue tumor requires a high index
of suspicion. The “two-week” target was clearly intended to
raise awareness of these tumours amongst the primary care
team and to shorten the wait for a patient with a suspicious
mass to be seen in a specialist clinic and therefore reduce the
delays in treatment. This is a laudable ambition. However,
the imposition of this kind of target for a selected group of
patients (those thought by a GP to be a priority) has the po-
tential to interfere with the delivery of rapid care to the re-
mainder [6]. It is important that patients with sarcomas re-
ferred by other routes are not disadvantaged by the prioriti-
sation of patients identiﬁed as urgent under the “two-week”
rule, particularly when the referral guidelines have not been
followed. We would like all patients with sarcoma to be seen
and treated in as short a time as possible, regardless of how
they are referred.
This was a retrospective study, limited by the data avail-
able. We were therefore unable to identify particular in-
stancesinwhichpatientsreferredwithbenignconditionsun-
der the “two-week” rule had been prioritised over patients
with sarcomas referred by other routes. However, the poten-
tial for this remains, particularly if the volume of cases re-
ferred under the “two-week” rule increases. We believe thatA. Malik et al. 3
clinicians working in a service are in the best position to dis-
tribute access to limited resources according to clinical need.
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